Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 4,566.00
+32.00 (0.71%)
Mar 27, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.14T JPY in the quarter ending December 31, 2024, with 2.96% growth. This brings the company's revenue in the last twelve months to 4.58T, up 9.83% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,579.02B
Revenue Growth
+9.83%
P/S Ratio
1.57
Revenue / Employee
92.92M
Employees
49,281
Market Cap
6,983.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTakeda Pharmaceutical Company News
- 14 days ago - Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
- 24 days ago - Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Benzinga
- 24 days ago - Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera - Business Wire
- 4 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - Benzinga
- 4 weeks ago - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 7 weeks ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha
- 2 months ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge - Business Wire